Portfolio
Portfolio

Ardana

Combined an in-licencing and M&A driven strategy to commercialize research carried out by the MRC and HRSU.

Combined an in-licencing and M&A driven strategy to commercialize research carried out by the Medical Research Council (MRC) Human Reproductive Sciences Unit (HRSU) in Edinburgh, Scotland. Ardana’s lead compound Teverellix was in phase IIa development for BPH and endometriosis. The company was listed on LSE but was unable to successfully develop its compounds.

Operations were discontinued in 2008.

  • Industry Biotech
  • History M&A